Revolution Medicines, Inc. (RVMD) shares ended the last trading session 11% higher at $43.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.7% loss over the past four weeks. The sudden soaring of the stock price can be attributed to the positive investor mindset regarding the progress in the development of Revolution's lead investigational candidate, RMC-6236. The company is currently evaluating RMC-6236 as a monotherapy as well as in combination with other agents in seprate early-stage studies across a variety of oncology indications. Revolution's clinical-stage pipeline also comprises two other early-stage candidates, being devolped for solid tumour indications. This company is expected to post quarterly loss of $0.75 per share in its upcoming report, which represents a year-over-year change of +18.5%. Revenues are expected to be $5.25 million, up 37.4% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For Revolution Medicines, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RVMD going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Revolution Medicines is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Assertio (ASRT), finished the last trading session 8.1% higher at $1.60. ASRT has returned 34.5% over the past month. Assertio's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. Compared to the company's year-ago EPS, this represents a change of -115.4%. Assertio currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Revolution Medicines, Inc. (RVMD):Free Stock Analysis Report Assertio Holdings, Inc. (ASRT):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...